Full Press Release Details
FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma.
REGN
FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
Key Takeaway: FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma